EMA Consults On Clinical Data Needed For Approving Hemophilia Non-Replacement Therapies
With several non-replacement therapies in the pipeline for hemophilia patients, the European Medicines Agency explains how sponsors of these products should go about their phase III confirmatory trials.
You may also be interested in...
Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Over 40 documents have been posted on the tracker since its last update.
The European pharmaceutical industry federation, EFPIA, says its member companies are not looking for shortcuts to develop and validate digital biomarkers, but want help from regulators to create the right evidence.
The European Medicines Agency has been on a steep learning curve with its qualification of a digitally-measured outcome for use in Duchenne muscular dystrophy trials, smoothing the way for other developers entering the digital biomarker space.